Provides business continuity update regarding COVID-19Continued execution across immuno-neurology platformOn track to initiate pivotal Phase 3 trial of AL001 in […]
Highlights Strong Business Momentum and Board’s Qualifications to Continue Driving Positive Business TrajectoryUrges Shareholders to Vote “FOR” ALL Its Director […]
CAMBRIDGE, Mass., May 13, 2020 (GLOBE NEWSWIRE) — Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and […]